Triple negative breast cancer: A difficult disease to diagnose and treat;Cáncer de mama triple negativo: Una enfermedad de difícil diagnóstico y tratamiento

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 30, Issue 4, 2013, Pages 649-656

  Zaharia, Mayer ^a   Gómez, Henry ^b  

^a AUNA Delgado Private Hospital   (Peru)

^b INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

Biological; Breast neoplasms; Epidemiology; Natural history of diseases; Risk factors; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AFRICAN AMERICAN; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL FEATURE; HEREDITY; HISPANIC; HUMAN; MORBIDITY; PUBLIC HEALTH; REVIEW; TRIPLE NEGATIVE BREAST CANCER; FEMALE; RISK FACTOR; TRIPLE NEGATIVE BREAST NEOPLASMS;

FEMALE; HUMANS; RISK FACTORS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84892600652     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast. 2010;19(5):312-21. doi: 10.1016/j.breast.2010.03.026.
2. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367-74.
3. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19/2):264-71.
4. Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O, Ozturk A. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol. 2010;27(1):34-9. doi: 10.1007/s12032-009-9166-3.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-2502.
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429-34.
7. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer [Internet]. Fort Washington, PA: NCCN; c2013 [citado el 12 de marzo del 2013]. Disponible en: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
8. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple-negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-34.
9. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2010;15 Suppl 5:39-48. doi: 10.1634/theoncologist.2010-S5-39.
10. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67. doi: 10.1172/JCI45014.
11. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010;10(4):294-300. doi: 10.3816/CBC.2010.n.038.
12. Márquez M, Lacruz JC, Borges LF. Sobrevida en pacientes con cáncer de mama triple negativo. Rev Obstet Ginecol Venez. 2012;72(3):152-60.
13. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, et al. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117(16):3658-69. doi: 10.1002/cncr.25961.
14. Amaral AL, Vitral I, Koifman S. Triple-negative breast cancer in brazilian women without metastasis to axillary lymph nodes: ten-year survival and prognostic factors. British Journal of Medicine & Medical Research. 2013;3(4):880-96.
15. Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95(19):1482-5.
16. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-8.
17. de Waard F. Breast cancer incidence and nutritional status with particular reference to body weight and height. Can Res. 1975;35(11 Pt. 2):3351-6.
18. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-91.
19. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(1):307-14. doi: 10.1007/s10549-012-2339-3.
20. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, et al. Age at first birth and breast cancer risk. Bull World Health Organ. 1970;43(2):209-21.
21. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 2011;103(6):470-7. doi: 10.1093/jnci/djr030.
22. Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, et al. Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control. 2011;22(5):775-83. doi: 10.1007/s10552-011-9750-7.
23. Grimm EE, Schmidt RA, Swanson PE, Dintzis SM, Allison KH. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol. 2010;134(2):284-92. doi: 10.1309/AJCPUQB18XZOHHBJ.
24. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst. 2008;100(3):218-21. doi: 10.1093/jnci/djm270.
25. Hefti MM, Hu R, Knoblauch N, Collins L, Tamimi RM, Beck AH. Discordant estrogen and progesterone receptor status in breast cancer. Cancer Res. 2012;72(24 Suppl 3). doi: 10.1158/0008-5472.SABCS12-P5-01-03.
26. Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010;6(4):195-7. doi: 10.1200/JOP.777003.
27. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984.
28. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist. 2013;18(2):123-33. doi: 10.1634/theoncologist.2012-0397
29. Cheang M, Martin M, Nielsen TO, Prat A, Rodriguez-Lescure A, Ruiz A, et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: a collaborative effort of the BIG-NCI NABCG. J Clin Oncol. 2012;30 suppl 1: abstr 1008.
30. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev.2005;14(5):1108-12.
31. Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol. 2012;23(12):2997-3006. doi: 10.1093/annonc/mds586.
32. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23. doi: 10.1016/S0140-6736(11)61539-0.
33. Luis IV, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Stephen B, et al. Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in women with T1N0 breast cancer (BC) in the National Comprehensive Cancer Network (NCCN). J Clin Oncol. 2013;31 suppl 1: abstr 1006.
34. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147.
35. Freedman G, Anderson P, Li T, Nicolaou N. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115(5):946-51. doi: 10.1002/cncr.24094.
36. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684-91. doi: 10.1200/JCO.2009.24.9284.
37. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831-41. doi: 10.1007/s10549-011-1891-6.
38. Garcés M, Pinto J, Marcelo M, Gómez H. Influencia de los subtipos de cáncer de mama determinados por inmunohistoquímica en la recurrencia local y a distancia en pacientes sometidas a cirugía como tratamiento inicial. Carcinos. 2012;2(1):3-12.
39. Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi31-4. doi: 10.1093/annonc/mdr373.
40. Aebi S, Davidson T, Gruber G, Cardoso F; ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi12-24. doi: 10.1093/annonc/mdr371.
41. Balko M, Wang K, Sanders ME, Kuba MG, Pinto JA, Doimi F, et al. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease. Cancer Research. 2012;72(24):S3-6. doi: 10.1158/0008-5472.SABCS12-S3-6
42. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725.